• 1
    Rogler G. Medical management of ulcerative colitis. Dig Dis 2009; 27: 5429.
  • 2
    Järnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 180511.
  • 3
    Laharie D, Bourreille A, Branche J, et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 2012; 380: 190915.
  • 4
    REMICADE® (infliximab). Summary of Product Characteristics (SPC). April 2011.
  • 5
    Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 246276.
  • 6
    Sandborn WJ, Rutgeerts P, Feagan BG, et al. Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology 2009; 137: 125060.
  • 7
    Reinisch W, Sandborn WJ, Rutgeerts P, et al. Long-term infliximab maintenance therapy for ulcerative colitis: the ACT-1 and -2 extension studies. Inflamm Bowel Dis 2012; 18: 20111.
  • 8
    Ferrante M, Vermeire S, Fidder H, et al. Long-term outcome after infliximab for refractory ulcerative colitis. J Crohn's Colitis 2008; 2: 21925.
  • 9
    Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterology 2010; 105: 261725.
  • 10
    Armuzzi A, Pugliese D, Danese S, et al. Infliximab in steroid-dependent ulcerative colitis: effectiveness and predictors of clinical and endoscopic remission. Inflamm Bowel Dis 2013 [Epub ahead of print].
  • 11
    Humira® (adalimumab). Summary of Product Characteristics (SPC). April 2012.
  • 12
    Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011; 60: 7807.
  • 13
    Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012; 142: 25765.
  • 14
    Sandborn WJ, Colombel JF, D'Haens G, et al. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2. Aliment Pharmacol Ther 2013; 37: 20413.
  • 15
    Taxonera C, Estellés J, Fernández-Blanco I, et al. Adalimumab induction and maintenance therapy for patients with ulcerative colitis previously treated with infliximab. Aliment Pharmacol Ther 2011; 33: 3408.
  • 16
    Gies N, Kroeker KI, Wong K, Fedorak RN. Treatment of ulcerative colitis with adalimumab or infliximab: long-term follow-up of a single-centre cohort. Aliment Pharmacol Ther 2010; 32: 5228.
  • 17
    Ochsenkühn T, D'Haens G. Current misunderstandings in the management of ulcerative colitis. Gut 2011; 60: 12949.
  • 18
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 15419.
  • 19
    Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 138395.
  • 20
    Panaccione R, Ghosh S, Middleton S, et al. Infliximab, azathioprine, or infliximab + azathioprine for treatment of moderate to severe ulcerative colitis: the UC SUCCESS trial. J Crohn's Colitis 2011; 5: S8.
  • 21
    Seow CH, Newman A, Irwin SP, Steinhart AH, Silverberg MS, Greenberg GR. Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis. Gut 2010; 59: 4954.
  • 22
    D'Haens GR, Panaccione R, Higgins PD, et al. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199212.
  • 23
    Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 16129.
  • 24
    Peyrin-Biroulet L, Cieza A, Sandborn WJ, et al. Development of the first disability index for inflammatory bowel disease based on the international classification of functioning, disability and health. Gut 2012; 61: 2417.
  • 25
    Cvancarova M, Solberg IC, Vatn MH, Moum B. Risk matrix model for prediction of disease severity in a population based study of Crohn Disease Patients. The IBSEN Study. Gastroenterology 2010; 138(5 Suppl 1): S529.
  • 26
    Simponi® (golimumab). Summary of Product Characteristics (SPC). February 2011.
  • 27
    Sandborn WJ, Feagan BG, Marano C, et al. A phase 2/3 randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of subcutaneous golimumab induction therapy in patients with moderately to severely active ulcerative colitis: PURSUIT SC. Presented at DDW 2012. Abstract 943d.
  • 28
    Lee SD, Osterman MT, Parrott SC, Wheat CL. Assessment of the efficacy and safety of certolizumab pegol for the treatment of moderate to severe ulcerative colitis. Gastroenterology 2012; 142(Suppl. 1): S–75.